[go: up one dir, main page]

ATE179703T1 - TRIAZOLE COMPOUNDS AND THEIR USE AS DOPAMINE D3 LIGANDS - Google Patents

TRIAZOLE COMPOUNDS AND THEIR USE AS DOPAMINE D3 LIGANDS

Info

Publication number
ATE179703T1
ATE179703T1 AT95926895T AT95926895T ATE179703T1 AT E179703 T1 ATE179703 T1 AT E179703T1 AT 95926895 T AT95926895 T AT 95926895T AT 95926895 T AT95926895 T AT 95926895T AT E179703 T1 ATE179703 T1 AT E179703T1
Authority
AT
Austria
Prior art keywords
dopamine
pct
ligands
triazole compounds
sec
Prior art date
Application number
AT95926895T
Other languages
German (de)
Inventor
Beate Hellendahl
Annegret Lansky
Rainer Munschauer
Siegfried Bialojan
Liliane Unger
Hans-Juergen Teschendorf
Karsten Wicke
Karla Drescher
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6523323&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE179703(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Basf Ag filed Critical Basf Ag
Application granted granted Critical
Publication of ATE179703T1 publication Critical patent/ATE179703T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

PCT No. PCT/EP95/02781 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02520 PCT Pub. Date Feb. 1, 1996The present invention relates to triazole compounds of the following formula: where R1, R2, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
AT95926895T 1994-07-15 1995-07-14 TRIAZOLE COMPOUNDS AND THEIR USE AS DOPAMINE D3 LIGANDS ATE179703T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4425144A DE4425144A1 (en) 1994-07-15 1994-07-15 Triazole compounds and their use

Publications (1)

Publication Number Publication Date
ATE179703T1 true ATE179703T1 (en) 1999-05-15

Family

ID=6523323

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95926895T ATE179703T1 (en) 1994-07-15 1995-07-14 TRIAZOLE COMPOUNDS AND THEIR USE AS DOPAMINE D3 LIGANDS

Country Status (23)

Country Link
US (1) US6124294A (en)
EP (1) EP0772604B1 (en)
KR (1) KR100379196B1 (en)
CN (1) CN1068314C (en)
AT (1) ATE179703T1 (en)
AU (1) AU703889B2 (en)
BG (1) BG63500B1 (en)
BR (1) BR9508294A (en)
CA (1) CA2195243C (en)
CZ (1) CZ292625B6 (en)
DE (2) DE4425144A1 (en)
DK (1) DK0772604T3 (en)
ES (1) ES2131842T3 (en)
FI (1) FI970147L (en)
GR (1) GR3030371T3 (en)
HU (1) HU225961B1 (en)
IL (1) IL114598A (en)
NO (1) NO315320B1 (en)
NZ (1) NZ290387A (en)
RU (1) RU2167869C2 (en)
SI (1) SI9520083A (en)
WO (1) WO1996002520A1 (en)
ZA (1) ZA955867B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19600934A1 (en) 1996-01-12 1997-07-17 Basf Ag Substituted aza and diazacycloheptane and cyclooctane compounds and their use
DE19728996A1 (en) * 1997-07-07 1999-01-14 Basf Ag Triazole compounds and their use
AU761018B2 (en) 1998-10-08 2003-05-29 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents)
TWI274750B (en) * 1999-01-12 2007-03-01 Abbott Gmbh & Co Kg Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same
AU7989400A (en) 1999-10-01 2001-05-10 Smithkline Beecham Corporation Compounds and methods
EP1272187B1 (en) * 2000-03-27 2008-07-30 Abbott GmbH & Co. KG Dopamine-d3 receptor ligands for the treatment of addiction
DE10109866A1 (en) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Triazole compounds and their use for the prophylaxis and therapy of neurodegenerative diseases, brain trauma and cerebral ischemia
DE10109867A1 (en) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Use of triazole compounds for the prophylaxis and therapy of neurodegenerative diseases, brain trauma and cerebral ischemia
MY133406A (en) * 2001-11-28 2007-11-30 Ipsen Pharma Sas 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as a medicament
CA2498936C (en) 2002-09-14 2013-02-12 Gov't Of The Usa As Represented By The Secretary Of The Department Of Health & Human Services Structurally rigid dopamine d3 receptor selective ligands and process for making them
HRP20050053A2 (en) * 2002-09-19 2005-04-30 Solvay Pharmaceuticals B.V. 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands
CZ300500B6 (en) * 2002-11-11 2009-06-03 Method for closing toes in knitting machine
RU2360910C2 (en) * 2002-12-20 2009-07-10 Мерк Энд Ко., Инк. Triazole derivatives as inhibitors of 11-beta-hydroxysteroiddehydrogenase-1
DE10304870A1 (en) * 2003-02-06 2004-08-19 Abbott Gmbh & Co. Kg Triazole compounds and their therapeutic use
JP2004359689A (en) * 2003-06-05 2004-12-24 Abbott Gmbh & Co Kg Triazole compound suitable for treating disorder responding to modulation of dopamine d3 receptor
US6919342B2 (en) 2003-06-05 2005-07-19 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
DE10358004A1 (en) 2003-12-11 2005-07-14 Abbott Gmbh & Co. Kg Ketolactam compounds and their use
US20050137186A1 (en) 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
JP4982184B2 (en) 2003-12-18 2012-07-25 アボット ゲーエムベーハー ウント カンパニー カーゲー Tetrahydrobenzazepine and their use in modulating dopamine D3 receptors
DE102004027358A1 (en) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidine compounds and their use
EP1798226A4 (en) * 2004-08-04 2009-06-17 Taisho Pharmaceutical Co Ltd triazole
ATE452134T1 (en) * 2004-08-09 2010-01-15 Abbott Gmbh & Co Kg 4-PIPERAZINYLPYRIMIDINE COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RESPONSIVE TO MODULATION OF THE DOPAMINE D3 RECEPTOR
KR20070106989A (en) * 2004-12-02 2007-11-06 애보트 게엠베하 운트 콤파니 카게 Triazole Compounds Suitable for Treatment of Disorders Responding to Modulation of Dopamine D₃ Receptors
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
RU2292339C1 (en) * 2005-05-23 2007-01-27 Государственное образовательное учреждение высшего профессионального образования "Южно-Российский государственный технический университет (Новочеркасский политехнический институт)" ГОУ ВПО ЮРГТУ (НПИ) Method for preparing 5-amino-1,2,4-triazol-3-ylcarboxylic acid amides
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
US8222254B2 (en) * 2007-08-07 2012-07-17 Prosarix Limited 1, 2, 4-triazole derivatives as serotonergic modulators
PA8802101A1 (en) 2007-11-02 2009-08-26 Abbott Gmbh & Co Kg SUITABLE 1,2,4-3,5-DIONA COMPOUNDS FOR THE TREATMENT OF DISORDERS THAT RESPOND TO THE MODULATION OF DOPAMINE D3 RECEIVER
SI2298747T1 (en) * 2008-07-03 2017-08-31 Astellas Pharma Inc. Triazole derivative or salt thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1053085A (en) * 1964-03-26
US4408049A (en) * 1980-09-17 1983-10-04 The Upjohn Company Substituted piperazinyl-1,2,4-triazoles
US4338453A (en) * 1980-09-17 1982-07-06 The Upjohn Company Aminoalkyl-1,2,4-triazoles
US4487773A (en) * 1981-03-16 1984-12-11 Mead Johnson & Company 1,2,4-Triazol-3-one antidepressants
US4338317A (en) * 1981-03-16 1982-07-06 Mead Johnson & Company Phenoxyethyl-1,2,4,-triazol-3-one antidepressants
US4577020A (en) * 1983-01-25 1986-03-18 The Upjohn Company Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents
US4575555A (en) * 1983-06-29 1986-03-11 Mead Johnson & Company 4-(3-Chlorophenyl)-1,2,3,6-tetrahydropyridine derivative
US4613600A (en) * 1983-09-30 1986-09-23 Mead Johnson & Company Antidepressant 1,2,4-triazolone compounds
DE3439450A1 (en) * 1984-10-27 1986-05-07 Boehringer Ingelheim KG, 6507 Ingelheim 1,2,4-TRIAZOLO-CARBAMATE AND ITS ACID ADDITION SALTS, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS
FR2580648B1 (en) * 1985-04-17 1987-05-15 Adir NOVEL TRIAZOLE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US4628059A (en) * 1985-10-31 1986-12-09 Smithklein Beckman Corporation Dopamine-β-hydroxylase inhibitors
FR2601952B1 (en) * 1986-07-23 1988-11-25 Carpibem NOVEL AMINO ALKYL THIO DERIVATIVES OF TRIAZOLOPYRIDINE OR TRIAZOLOQUINOLINE, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS CONTAINING THEM, USEFUL IN PARTICULAR AS ANTALGICS
US4761415A (en) * 1986-08-28 1988-08-02 Smithkline Beckman Corporation Dopamine-β-hydroxylase inhibitors
FR2672052B1 (en) * 1991-01-28 1995-05-24 Esteve Labor Dr DERIVATIVES OF ARYL (OR HETEROARYL) -PIPERAZINYL-ALKYL-AZOLES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS.
GB9021535D0 (en) * 1990-10-03 1990-11-14 Wyeth John & Brother Ltd Piperazine derivatives
US5256664A (en) * 1992-04-28 1993-10-26 Bristol-Myers Squibb Company Antidepressant 3-halophenylpiperazinylpropyl derivatives of substituted triazolones and triazoldiones

Also Published As

Publication number Publication date
AU3111395A (en) 1996-02-16
WO1996002520A1 (en) 1996-02-01
KR970704710A (en) 1997-09-06
CZ9797A3 (en) 1997-08-13
DE59505853D1 (en) 1999-06-10
FI970147A7 (en) 1997-01-14
NO315320B1 (en) 2003-08-18
NO970161D0 (en) 1997-01-14
GR3030371T3 (en) 1999-09-30
CZ292625B6 (en) 2003-11-12
HUT77128A (en) 1998-03-02
DK0772604T3 (en) 1999-11-01
RU2167869C2 (en) 2001-05-27
JPH10502914A (en) 1998-03-17
FI970147A0 (en) 1997-01-14
FI970147L (en) 1997-01-14
CN1152919A (en) 1997-06-25
CA2195243A1 (en) 1996-02-01
ZA955867B (en) 1997-01-14
EP0772604A1 (en) 1997-05-14
IL114598A0 (en) 1995-11-27
NZ290387A (en) 1999-02-25
CA2195243C (en) 2006-05-30
CN1068314C (en) 2001-07-11
US6124294A (en) 2000-09-26
IL114598A (en) 1999-12-22
DE4425144A1 (en) 1996-01-18
JP4114950B2 (en) 2008-07-09
BG101113A (en) 1998-04-30
NO970161L (en) 1997-03-14
BG63500B1 (en) 2002-03-29
SI9520083A (en) 1997-10-31
HU225961B1 (en) 2008-01-28
KR100379196B1 (en) 2003-06-11
ES2131842T3 (en) 1999-08-01
EP0772604B1 (en) 1999-05-06
HU9700109D0 (en) 1997-02-28
BR9508294A (en) 1997-12-30
AU703889B2 (en) 1999-04-01

Similar Documents

Publication Publication Date Title
DE59505853D1 (en) TRIAZOLIC COMPOUNDS AND THEIR USE AS DOPAMINE D3 LIGANDS
DE59510635D1 (en) USE OF HETEROCYCLIC COMPOUNDS AS DOPAMIN-D 3 LIGANDS
DE59510244D1 (en) SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE
ATE234616T1 (en) THIADIAZOLE COMPOUNDS AS D3 DOPAMINE RECEPTOR LIGAND
PL318297A1 (en) Dihydrobenzofuranes
MX9700125A (en) Substituted pyrimidine compounds and their use.